| pubmed-article:2011916 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C0033235 | lld:lifeskim |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:2011916 | lifeskim:mentions | umls-concept:C1709708 | lld:lifeskim |
| pubmed-article:2011916 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2011916 | pubmed:dateCreated | 1991-5-6 | lld:pubmed |
| pubmed-article:2011916 | pubmed:abstractText | The effect of increasing doses of growth hormone on collagen synthesis in GH-treated GH-deficient patients was determined in a short-term study. The synthesis of type I and III collagen was estimated by measurements of the carboxyterminal propeptide of type I procollagen and the aminoterminal propeptide of type III procollagen. Type I collagen is mainly found in bone and type III collagen in loose connective tissue. We observed a GH dose dependency of both procollagen propeptides. Serum type I procollagen propeptide was significantly higher following GH doses of 4 and 6 IU/day for 14 days compared with 2 IU/day (normal replacement dose) (p = 0.04). Withdrawal of GH therapy for 14 days resulted in wider variation, but not significantly different from the levels at 2, 4 and 6 IU/day. A dose dependency was found regarding type III procollagen propeptide, showing significantly higher serum concentrations at a GH dose of 4 IU/day compared with 2 IU/day (p = 0.001), and of 6 IU/day compared with 4 IU/day (p = 0.001). Withdrawal of GH therapy resulted in significantly lower type III procollagen propeptide concentrations compared with those at a GH dose of 4 and 6 IU/day (p = 0.03). Serum type III procollagen propeptide increased twice as much as type I procollagen propeptide, by 47 vs 25%, at a GH dose of 6 IU/day compared with 2 IU/day. The differences between the effects on type I and type III collagen may reflect differences in secretion or turn-over rate of collagen in bone and loose connective tissue.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2011916 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2011916 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2011916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011916 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2011916 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:2011916 | pubmed:issn | 0001-5598 | lld:pubmed |
| pubmed-article:2011916 | pubmed:author | pubmed-author:LorenzenII | lld:pubmed |
| pubmed-article:2011916 | pubmed:author | pubmed-author:ChristiansenJ... | lld:pubmed |
| pubmed-article:2011916 | pubmed:author | pubmed-author:RisteliJJ | lld:pubmed |
| pubmed-article:2011916 | pubmed:author | pubmed-author:JørgensenJ... | lld:pubmed |
| pubmed-article:2011916 | pubmed:author | pubmed-author:JensenL TLT | lld:pubmed |
| pubmed-article:2011916 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2011916 | pubmed:volume | 124 | lld:pubmed |
| pubmed-article:2011916 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2011916 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2011916 | pubmed:pagination | 278-82 | lld:pubmed |
| pubmed-article:2011916 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:meshHeading | pubmed-meshheading:2011916-... | lld:pubmed |
| pubmed-article:2011916 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2011916 | pubmed:articleTitle | Type I and III procollagen propeptides in growth hormone-deficient patients: effects of increasing doses of GH. | lld:pubmed |
| pubmed-article:2011916 | pubmed:affiliation | Department of Rheumatology 232, Hvidovre Hospital, University of Copenhagen, Denmark. | lld:pubmed |
| pubmed-article:2011916 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2011916 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
